WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.
Immunotherapy using a Wilms tumor (WT1) peptide has been undergoing clinical trials for adulthood leukemia and solid cancer with promising results. In this study, the authors used WT1 peptide vaccination to treat a 6-year-old girl with metastatic alveolar rhabdomyosarcoma. She received weekly intradermal injection with HLA-A*2404-restricted, 9-mer WT1 peptide against residual bone disease. After 3 months her bone disease disappeared, concurrent with an increase in the frequency of WT1-specific cytotoxic T lymphocytes (CTLs). A high proportion of WT1-specific CTLs with effector or effector memory phenotype were detected in peripheral blood of this patient. She is currently still on continued WT1 peptide immunotherapy in a disease-free condition for 22 months. WT1 peptide-based immunotherapy should be a promising option for high-risk rhabdomyosarcoma in childhood.
Ohta
Hideaki
H
Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. ohta@ped.med.osaka-u.ac.jp
Hashii
Yoshiko
Y
Yoneda
Akihiro
A
Takizawa
Sachiko
S
Kusuki
Shigenori
S
Tokimasa
Sadao
S
Fukuzawa
Masahiro
M
Tsuboi
Akihiro
A
Murao
Ayako
A
Oka
Yoshihiro
Y
Oji
Yusuke
Y
Aozasa
Katsuyuki
K
Nakatsuka
Shin-ichi
S
Sugiyama
Haruo
H
Ozono
Keiichi
K
D001847:Bone Diseases / Q000188:drug therapy; D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D010446:Peptide Fragments / Q000627:therapeutic use*; D018232:Rhabdomyosarcoma, Alveolar / Q000188:drug therapy* / Q000473:pathology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014611:Vaccination; D025721:WT1 Proteins / Q000627:therapeutic use*
D010446:Peptide Fragments; D025721:WT1 Proteins